Laura Iop

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5762566/laura-iop-publications-by-year.pdf
Version: 2024-04-23

45 papers	1,444 citations	21 h-index	37 g-index
52 ext. papers	1,713 ext. citations	7.5 avg, IF	4.48 L-index

#	Paper	IF	Citations
45	Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	3
44	Bioengineered percutaneous heart valves for transcatheter aortic valve replacement: a comparative evaluation of decellularised bovine and porcine pericardia. *Materials Science and Engineering C*, **2021**, 123, 111936	8.3	1
43	Role of coronary microvascular dysfunction in heart failure with preserved ejection fraction. *Reviews in Cardiovascular Medicine*, **2021**, 22, 97-104	3.9	2
42	Bioengineering the Cardiac Conduction System: Advances in Cellular, Gene, and Tissue Engineering for Heart Rhythm Regeneration. *Frontiers in Bioengineering and Biotechnology*, **2021**, 9, 673477	5.8	2
41	Hybrid membranes for the production of blood contacting surfaces: physicochemical, structural and biomechanical characterization. *Biomaterials Research*, **2021**, 25, 26	16.8	5
40	Covalent functionalization of decellularized tissues accelerates endothelialization. *Bioactive Materials*, **2021**, 6, 3851-3864	16.7	3
39	A Comprehensive Comparison of Bovine and Porcine Decellularized Pericardia: New Insights for Surgical Applications. *Biomolecules*, **2020**, 10,	5.9	20
38	RegenHeart: A Time-Effective, Low-Concentration, Detergent-Based Method Aiming for Conservative Decellularization of the Whole Heart Organ. *ACS Biomaterials Science and Engineering*, **2020**, 6, 5493-5506	5.5	2
37	Toward the Effective Bioengineering of a Pathological Tissue for Cardiovascular Disease Modeling: Old Strategies and New Frontiers for Prevention, Diagnosis, and Therapy. *Frontiers in Cardiovascular Medicine*, **2020**, 7, 591583	5.4	1
36	The Biocompatibility Challenges in the Total Artificial Heart Evolution. *Annual Review of Biomedical Engineering*, **2019**, 21, 85-110	12	12
35	Fibrosis in tissue engineering and regenerative medicine: treat or trigger?. *Advanced Drug Delivery Reviews*, **2019**, 146, 17-36	18.5	11
34	Preservation strategies for decellularized pericardial scaffolds for off-the-shelf availability. *Acta Biomaterialia*, **2019**, 84, 208-221	10.8	20
33	Native Bovine and Porcine Pericardia Respond to Load With Additive Recruitment of Collagen Fibers. *Artificial Organs*, **2018**, 42, 540-548	2.6	7
32	Multimodal label-free ex vivo imaging using a dual-wavelength microscope with axial chromatic aberration compensation. *Journal of Biomedical Optics*, **2018**, 23, 1-9	3.5	14
31	A sterilization method for decellularized xenogeneic cardiovascular scaffolds. *Acta Biomaterialia*, **2018**, 67, 282-294	10.8	36
30	Bioengineered tissue solutions for repair, correction and reconstruction in cardiovascular surgery. *Journal of Thoracic Disease*, **2018**, 10, S2390-S2411	2.6	24
29	Interplay of cell-cell contacts and RhoA/MRTF-A signaling regulates cardiomyocyte identity. *EMBO Journal*, **2018**, 37,	13	46

28	In vitro comparative assessment of decellularized bovine pericardial patches and commercial bioprosthetic heart valves. *Biomedical Materials (Bristol)*, **2017**, 12, 015021	3.5	28
27	Decellularized Cryopreserved Allografts as Off-the-Shelf Allogeneic Alternative for Heart Valve Replacement: In Vitro Assessment Before Clinical Translation. *Journal of Cardiovascular Translational Research*, **2017**, 10, 93-103	3.3	18
26	The Rapidly Evolving Concept of Whole Heart Engineering. *Stem Cells International*, **2017**, 2017, 8920940	5	17
25	The Light and Shadow of Senescence and Inflammation in Cardiovascular Pathology and Regenerative Medicine. *Mediators of Inflammation*, **2017**, 2017, 7953486	4.3	8
24	The Vietnamese pig as a translational animal model to evaluate tissue engineered heart valves: promising early experience. *International Journal of Artificial Organs*, **2017**, 40, 142-149	1.9	9
23	Mechanical testing of pericardium for manufacturing prosthetic heart valves. *Interactive Cardiovascular and Thoracic Surgery*, **2016**, 22, 72-84	1.8	38
22	Nanopatterned acellular valve conduits drive the commitment of blood-derived multipotent cells. *International Journal of Nanomedicine*, **2016**, 11, 5041-5055	7.3	3
21	Decellularized aortic conduits: could their cryopreservation affect post-implantation outcomes? A morpho-functional study on porcine homografts. *Heart and Vessels*, **2016**, 31, 1862-1873	2.1	21
20	Guided tissue regeneration in heart valve replacement: from preclinical research to first-in-human trials. *BioMed Research International*, **2015**, 2015, 432901	3	25
19	Are FDA and CE sacrificing safety for a faster commercialization of xenogeneic tissue devices? Unavoidable need for legislation in decellularized tissue manufacturing. *Tissue Antigens*, **2014**, 83, 193-4		12
18	Extracellular pyrophosphate is reduced in aortic interstitial valve cells acquiring a calcifying profile: implications for aortic valve calcification. *Atherosclerosis*, **2014**, 237, 568-76	3.1	18
17	Modeling Cardiac Congenital Diseases: From Mathematic Tools to Human Induced Pluripotent Stem Cells. *Conference Papers in Science*, **2014**, 2014, 1-9		2
16	Biocompatibility Issues of Next Generation Decellularized Bioprosthetic Devices. *Conference Papers in Science*, **2014**, 2014, 1-6		2
15	Decellularized allogeneic heart valves demonstrate self-regeneration potential after a long-term preclinical evaluation. *PLoS ONE*, **2014**, 9, e99593	3.7	61
14	Cellular, molecular, genomic changes occurring in the heart under mechanical circulatory support. *Annals of Cardiothoracic Surgery*, **2014**, 3, 496-504	4.7	5
13	Present and future perspectives on total artificial hearts. *Annals of Cardiothoracic Surgery*, **2014**, 3, 595-602	4.7	28
12	First quantification of alpha-Gal epitope in current glutaraldehyde-fixed heart valve bioprostheses. *Xenotransplantation*, **2013**, 20, 252-61	2.8	84
11	Cutting-Edge Regenerative Medicine Technologies for the Treatment of Heart Valve Calcification **2013**,		2

10	Alpha-Gal detectors in xenotransplantation research: a word of caution. *Xenotransplantation*, **2012**, 19, 215-20	2.8	45
9	Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. *EMBO Molecular Medicine*, **2012**, 4, 180-91	12	257
8	First quantitative assay of alpha-Gal in soft tissues: presence and distribution of the epitope before and after cell removal from xenogeneic heart valves. *Acta Biomaterialia*, **2011**, 7, 1728-34	10.8	53
7	Proteomic analysis of clonal interstitial aortic valve cells acquiring a pro-calcific profile. *Journal of Proteome Research*, **2010**, 9, 5913-21	5.6	27
6	Human bone marrow-derived CD133(+) cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. *Cell Transplantation*, **2010**, 19, 1247-60	4	31
5	The influence of heart valve leaflet matrix characteristics on the interaction between human mesenchymal stem cells and decellularized scaffolds. *Biomaterials*, **2009**, 30, 4104-16	15.6	68
4	Clones of interstitial cells from bovine aortic valve exhibit different calcifying potential when exposed to endotoxin and phosphate. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 2165-72	9.4	41
3	Different cardiovascular potential of adult- and fetal-type mesenchymal stem cells in a rat model of heart cryoinjury. *Cell Transplantation*, **2008**, 17, 679-94	4	56
2	Neovascularization induced by porous collagen scaffold implanted on intact and cryoinjured rat hearts. *Biomaterials*, **2007**, 28, 5449-61	15.6	68
1	Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. *Journal of Molecular and Cellular Cardiology*, **2007**, 42, 746-59	5.8	127